Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients With Depressive Episodes

Inclusion Criteria: * Men or women over the age of 18 * Psychiatric diagnosis: * Presenting a depressive episode characterised according to DSM-5 criteria * MADRS score greater than or equal to 20, indicating moderate to severe depression * Indication and prescription of a course of tDCS treatment consisting of 20 sessions of 30 minutes at 2mA, at a rate of 2 sessions per day * Drug treatment: o Failure of a maximum of 1 or 2 antidepressants taken successively or in combination for the current episode * Psychiatric follow-up: Receiving medical follow-up by a psychiatrist or referring physician * Ability to understand and cooperate: * Having a smartphone, computer or tablet (with internet connection and Bluetooth) to use the digital interface required to perform remote tDCS * Be deemed capable of understanding the nature of the study and participating in clinical follow-up * Informed consent: Have given written consent to participate in the research, after receiving oral and written information about the study. * Social affiliation: Be affiliated with a social security system Exclusion Criteria: * Psychiatric or neurological diagnoses: * Chronic psychotic disorders or history of schizophrenia * Progressive neurological disorders (unstabilised epilepsy, brain tumour, recent stroke, severe head injury) * History or current treatment of neuromodulation * Any history of tDCS treatment, whether carried out in a clinical or research setting * Current treatment or history of rTMS and ECT sessions for the current episode * Presence of an active vagus nerve stimulation implant * Presence of a high risk of suicide. A risk of suicide will be considered high if the score on item 10 of the MADRS scale ("Suicidal Thoughts") is 4 or higher, and/or if there is active suicidal ideation accompanied by clinically identified intent or a plan * Addiction and substance use: Current substance use disorder other than nicotine or caffeine * Psychiatric comorbidities that may interfere with study participation, including: understanding information, adherence to the protocol, and completing CBT sessions. * Recent change in curative psychotropic treatment (antidepressant, mood stabiliser including lithium and anticonvulsants, mood-stabilising antipsychotic) in the month prior to inclusion. * Medical contraindication to stimulation: * Presence of a metallic or electronic implant in the skull or chest (pacemaker, neurostimulator, cochlear implant) * Skin lesion, irritation or wound on the electrode contact areas * History of epileptic seizures not related to an identified cause or not stabilised for more than 12 months * Current pregnancy or breastfeeding * Women of childbearing age without effective contraception (hormonal or medical device) * A severe and/or progressive somatic condition requiring ongoing medical care that would interfere with participation in the study. * Limited ability to participate: * A significant cognitive impairment or sensory deficit that prevents understanding of instructions * Inability to safely perform tDCS at home, as defined by at least one of the following: * inability to understand or recall essential instructions regarding procedure and safety; * inability to perform, following initial guidance, the essential steps for setting up and starting the device; * lack of the minimum material conditions required at home to conduct the sessions. * Special legal or social situation: * Patients under guardianship, curatorship or judicial protection * Privation of liberty by judicial or administrative decision, Presence of a functional limitation to the independent performance of tDCS